公开(公告)号：US20240109977A1

公开(公告)日：2024-04-04

申请号：US18261376

申请日：2022-01-14

Applicant: MORPHOSYS AG

Inventor： Stefan Steidl ,  Stefan Härtle ,  Rainer Boxhammer

IPC: C07K16/28 ,  A61P13/12 ,  A61P37/06

CPC classification number: C07K16/2896 ,  A61P13/12 ,  A61P37/06 ,  A61K2039/505

Abstract: The present invention relates to the use of an anti-CD38 antibody or antibody fragment in the prophylaxis and/or treatment of diseases directly caused by immune complex deposits. In accordance with the present invention, an anti-CD38 antibody is effective in the treatment of IgA nephropathy (IgAN).

公开(公告)号：US20150246969A1

公开(公告)日：2015-09-03

申请号：US14429996

申请日：2013-09-19

Applicant: MORPHOSYS AG

Inventor： Stefan Hartle ,  Stephane Leclair ,  Amgad Shebl ,  Stefan Steidl

IPC: C07K16/24 ,  A61K31/519 ,  A61K39/395

Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

Abstract translation: 本发明提供用于治疗类风湿性关节炎的抗GM-CSF抗体。 将抗GM-CSF抗体，特别是MOR103，以有利于临床环境的剂量施用于患有类风湿性关节炎的患者。